4//SEC Filing
Brady Stephen R 4
Accession 0001209191-19-023687
CIK 0001437786other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 5:15 PM ET
Size
17.4 KB
Accession
0001209191-19-023687
Insider Transaction Report
Form 4
Brady Stephen R
Chief Business Officer
Transactions
- Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−120,000→ 0 totalExercise: $1.31→ Common Stock (120,000 underlying) - Disposition to Issuer
Common Stock
2019-04-02$5.85/sh−17,063$99,819→ 0 total - Disposition to Issuer
Restricted Stock Units
2019-04-02−79,536→ 0 totalExercise: $0.00→ Common Stock (79,536 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−116,819→ 0 totalExercise: $1.23→ Common Stock (116,819 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−100,000→ 0 totalExercise: $4.05→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (Rt to Buy)
2019-04-02−184,364→ 0 totalExercise: $4.40→ Common Stock (184,364 underlying)
Footnotes (4)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
- [F2]Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards.
- [F3]Not Applicable.
- [F4]Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share.
Documents
Issuer
IMMUNE DESIGN CORP.
CIK 0001437786
Entity typeother
Related Parties
1- filerCIK 0001606241
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 5:15 PM ET
- Size
- 17.4 KB